Sven Dethlefs Net Worth

The estimated Net Worth of Sven Dethlefs is at least $4.09 Milhão dollars as of 6 March 2023. Mr. Dethlefs owns over 77,421 units of Teva- Pharmaceutical Industries stock worth over $2,970,243 and over the last 7 years he sold TEVA stock worth over $1,115,718. In addition, he makes $0 as Executive Vice President - Global Marketing & Portfolio at Teva- Pharmaceutical Industries.

Mr. Dethlefs TEVA stock SEC Form 4 insiders trading

Sven has made over 15 trades of the Teva- Pharmaceutical Industries stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 77,421 units of TEVA stock worth $739,371 on 6 March 2023.

The largest trade he's ever made was selling 77,421 units of Teva- Pharmaceutical Industries stock on 6 March 2023 worth over $739,371. On average, Sven trades about 15,511 units every 64 days since 2018. As of 6 March 2023 he still owns at least 165,381 units of Teva- Pharmaceutical Industries stock.

You can see the complete history of Mr. Dethlefs stock trades at the bottom of the page.

Sven Dethlefs biography

Sven Dethlefs Ph.D. serves as Executive Vice President - Global Marketing & Portfolio of the Company. From 2016 to 2017, he served as Global Head of Respiratory Medicines, Global Specialty Medicines. From 2013 to 2016, he served as Chief Operating Officer, Teva Global Operations. Mr. Dethlefs joined Teva as General Manager, Teva Germany in 2008. Prior to joining Teva, he served for over eleven years as a partner at McKinsey & Company. Mr. Dethlefs received his Ph.D. in biochemistry from the FU Berlin/Pasteur Institute Paris.

How old is Sven Dethlefs?

Sven Dethlefs is 51, he's been the Executive Vice President - Global Marketing & Portfolio of Teva- Pharmaceutical Industries since 2017. There are 20 older and 7 younger executives at Teva- Pharmaceutical Industries. The oldest executive at Teva- Pharmaceutical Industries Ltd. is Gerald Lieberman, 73, who is the Independent Director.

What's Sven Dethlefs's mailing address?

Sven's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.

Insiders trading at Teva- Pharmaceutical Industries

Over the last 7 years, insiders at Teva- Pharmaceutical Industries have traded over $31,332,399 worth of Teva- Pharmaceutical Industries stock and bought 967,500 units worth $16,473,820 . The most active insiders traders include Sol J Barer, Tal Zvi Zaks, eRoberto Mignone. On average, Teva- Pharmaceutical Industries executives and independent directors trade stock every 9 days with the average trade being worth of $636,538. The most recent stock trade was executed by Varda Shalev on 2 September 2024, trading 12,872 units of TEVA stock currently worth $231,181.

What does Teva- Pharmaceutical Industries do?

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company with headquarters in Tel Aviv, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.

Complete history of Mr. Dethlefs stock trades at Teva- Pharmaceutical Industries

Teva- Pharmaceutical Industries executives and stock owners

Teva- Pharmaceutical Industries executives and other stock owners filed with the SEC include:

• Kaare Schultz,
  President, Chief Executive Officer, Director
• Kare Schultz,
  Pres, CEO & Director
• Mark Sabag,
  Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
• Hafrun Fridriksdottir,
  Executive Vice President - Global R&D
• Brendan O'Grady,
  Executive Vice President - North America Commercial
• Gianfranco Nazzi,
  Executive Vice President - International Markets Commercial
• Dr. Hafrun Fridriksdottir,
  Exec. VP of Global R&D
• Gianfranco Nazzi,
  Exec. VP of International Markets Commercial
• Eric Drape,
  Exec. VP of Global Operations
• Eliyahu Sharon Kalif,
  Exec. VP & CFO
• Sol Barer,
  Independent Chairman of the Board
• Nechemia Peres,
  Independent Director
• Gerald Lieberman,
  Independent Director
• Amir Elstein,
  Independent Director
• Roberto Mignone,
  Independent Director
• Rosemary Crane,
  Independent Director
• Jean-Michel Halfon,
  Independent Director
• Perry Nisen,
  Independent Director
• Ronit Satchi-Fainaro,
  Independent Director
• Eliyahu Kalif,
  Chief Financial Officer, Executive Vice President
• Kevin Mannix,
  Senior Vice President, Investor Relations
• Janet Vergis,
  Independent Director
• Abbas Hussain,
  Independent Director
• David Stark,
  Executive Vice President, Chief Legal Officer
• Eric Drape,
  Executive Vice President - Global Operations
• Sven Dethlefs,
  Executive Vice President - Global Marketing & Portfolio
• Richard Daniell,
  Executive Vice President - European Commercial
• Eli Shani,
  Exec. VP of Global Marketing & Portfolio
• Galia Inbar,
  Exec. VP, Chief HR Officer and Head of Global Communications, Brand & ESG
• David M. Stark,
  Exec. VP & Chief Legal Officer
• Amir Weiss,
  Sr. VP & Chief Accounting Officer
• Lori Queisser,
  Sr. VP & Global Compliance Officer
• Andrew J. Weil CPA,
  Chief Accounting Officer
• Eric Drapé,
  Exec. VP of Global Operations
• Iris Beck Codner,
  EVP Global Brand&Communication
• Kare Schultz,
  President and CEO
• Michael James Mc Clellan,
  EVP, Chief Financial Officer
• Notaristefani Carlo De,
  Executive VP Global Operations
• Placid Jover,
  See "Remarks"
• Deborah A Griffin,
  Chief Accounting Officer
• Varda Shalev,
  
• Dan S Suesskind,
  Director
• Murray A Goldberg,
  Director
• Dov Bergwerk,
  Acting Chief Legal Officer
• David R. Mc Avoy,
  EVP, Chief Legal Officer
• Andrew Weil,
  Chief Accounting Officer
• Galia Inbar,
  See "Remarks"
• Eli Shani,
  EVP,Global Marketing&Portfolio
• Angus Grant,
  EVP, Business Development
• Eric A Hughes,
  See "Remarks"
• Vikki L Conway,
  See "Remarks"
• Christine Fox,
  EVP, Head of U.S. Commercial
• Amir Weiss,
  Chief Accounting Officer
• Richard D Francis,
  President and CEO
• Matthew Shields,
  EVP, Global Operations
• Tal Zvi Zaks,